Pharmaceuticals

Executive Summary Investment Thesis: Pfizer is experiencing a significant post-COVID earnings normalization after unprecedented vaccine-driven profits. Trading at $26.43 with a P/E of 17.7x and P/B of 1.69x, the stock offers potential turnaround value but faces execution risks as management navigates patent cliffs, integrates acquisitions, and rebuilds the pipeline. The business fails most defensive investor criteria but may reward patient capital if operational improvements materialize. Business Classification: Cyclical/Turnaround Current Valuation Assessment: ...

Executive Summary Investment Thesis: Novo Nordisk represents a rare opportunity to buy a dominant healthcare franchise at a 65% discount. The GLP-1 obesity market is in early innings, yet Mr. Market is pricing in catastrophic competitive loss despite 25% revenue growth, 79% ROE, and 44% operating margins. Business Classification: Fast Grower (20%+ growth in large, expanding market) Current Valuation Assessment: Current Price: $50.26 Estimated Intrinsic Value: $90-110 Margin of Safety: 49% Recommendation: STRONG BUY Recommended Entry Zones: ...